Material and methods

Cell culture
Human breast cancer MDA-MB-231 cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% foetal calf serum, L-glutamine (2 mM), penicillin (100 U/ml) and streptomycin (100 g/ml) at 37ЊC in a 5% CO2 humid atmosphere. All culture reagents were purchased from
Gibco-Life Technologies (Invitrogen Corporation, Paisley, Scotland). MDA-MB-231 cells stably expressing (MT4 clones) or not (CTR clones) MT4-MMP
were obtained as previously described [18] 6 ) were subcutaneously injected with matrigel (200 l) in mice flank (n ϭ 10) as previously described [18] . In the experimental metastasis model, cells were detached in PBS-ethylenediaminetetraacetic acid 5 mM, resuspended in serum-free medium (20 ϫ 10 6 cells/ml) and injected (1 ϫ 10 6 protein as previously described [18] . The Fig. 4 are simplified for a better visibility, the grids used for the quantifications were drawn at three concentric rings/micrometre. 
Metastasis assays
Metastatic potential of MDA-MB-231 cells expressing or not MT4-MMP was investigated with two distinct models of metastasis in immunodeficient mice : (i) a 'spontaneous' model of lung metastasis from a subcutaneous primary tumour and (ii) an 'experimental' model in which lung metastasis were directly induced by intravenous injection of the tumour cells. In the spontaneous model, tumour cells (1 ϫ
10
cells in 50 l) into the lateral tail vein of the mice (n ϭ 10). For each model of metastasis, either Rag-1 deficient mice or athymic nude mice (Charles River Laboratories, Lyon, France) were injected with tumour cells. Similar results were observed in both immunodeficient backgrounds. Metastases were detected 6 or 8 weeks after injection by histological, in vivo or ex vivo bioluminescence analyses. For histological analyses, paraffin-embedded organs were cut at 5-mthick and metastasis were detected by immunostaining for human
Vascular morphometric measurements
Thick sections of xenografts expressing (n ϭ 10) or not (n ϭ 5) MT4-MMP were observed with a fluorescent microscope (Olympus, Aartselaar, Belgium) at 200-fold magnification. The whole surface of tumour sections was scanned and photomicrographed (50-100/section). The mean vessel density was calculated by counting the number of intratumour blood vessels present either on the whole area sections or on the most vascularised area ('hot spots') of the sections. The cross-sectioned area and the size distribution of the blood vessels were analysed using ImageJ software (http://rsb.info.nih.gov/ij/). According to previous studies [23, 25], one of the following diameter categories was assigned to each vessel : Ͻ25 m (small), between 25 and 50 m (medium) or Ն50 m (large). In order to analyse the mural cells distribution around the blood vessels, an original computer-assisted quantification was developed by implementing an algorithm in MATLAB software (http://www.mathworks.com/): concentric rings were drown all around the vessels by successive dilatation of vessels shape at similar intervals of distance. The densities of red pixels (mural cells) crossed by this grid were then calculated as a distance function from the green pixels (endothelial cells). Although the grids shown in
Evaluation of tumour vascular leakage
Six weeks after tumour cell injection, xenografted nude mice (n ϭ 3) were anesthetized with isofurane (1-3%) and intravenously injected with 150 l (2 mM in PBS) of AngioSense™ 680 vascular probe (VisEn
Statistical analysis
Statistical differences between experimental groups were assessed using the non- [18] . (Fig. 1A , right panels). (Fig. 1B) . However, no significant difference in the incidence of lymph node metastasis was observed between MT4-MMP expressing or control cells (Fig. 1B) . Altogether, these data suggest that MT4-MMP expression improves lung metastasis but not lymphatic dissemination.
Results
MT4-MMP overexpression does not affect lymph node metastasis
MT4-MMP overexpression in MDA-MB-231 cells has been previously associated with higher levels of lung metastases when subcutaneously injected into mice
Fig. 1 Effect of MT4-MMP on tumour lymphatic network and lymph node metastasis. The tumour lymphatic network (A) and the presence of lymph node metastasis (B) were analysed in athymic nude mice after subcutaneous injection of MDA-MB-231 breast cancer cells expressing (MT4-xenografted mice; upper panels) or not (CTR-xenografted mice; lower panels) MT4-MMP. (A) Lymphatic vessels were detected at the interface between the tumours (T ) and the host stroma (S ) by LYVE-1 immunostaining of xenograft sections (left panel ). Functionality of tumour lymphatic network was assessed by lateral (middle panel) and ventral (right panel ) visualization of sentinel lymph nodes 24 hrs after intratumoral injection of fluorescent nanocrystals (Qdot ). Black arrows indicate accumulated Qdot particules in the regional (inguinal; I ) and distal (auxiliary; A) lymph nodes. (B) The presence of regional (inguinal; I ) and distal (auxiliary; A) lymph node (LN ) metastases as well as lung metastases were detected by bioluminescent analysis of the luciferase reporter gene in each organ ex vivo. Percentage represents the incidence of mice with detectable metastasis in each organ (n ϭ 10).
To confirm by bioluminescence imaging (BLI) that MT4-MMP promotes lung metastasis from subcutaneous grafts, cells expressing MT4-MMP and luciferase or their control clones have been generated (Figs 1B and 2A). We checked by RT-PCR and Western blot that luciferase expression did not affect MT4-MMP production (data not shown). Due to the high bioluminescence signal from the primary tumour, weak bioluminescence signal from micro-metastases were difficult to access directly in vivo. Therefore ex vivo analyses were also performed on lymph nodes and lungs recovered 8 weeks after subcutaneous injection of cancer cells (Fig. 1B). Lung metastasis was clearly increased after the injection of cells expressing MT4-MMP compared with control cells (60% versus 0%)
MT4-MMP overexpression does not affect extravasation from the blood to the lungs
To distinguish between an effect on primary invasion (subcutaneous injection) and extravasation from the bloodstream, cells expressing MT4-MMP and luciferase or their controls were alternatively injected via the tail vein. In these conditions, in sharp contrast to the xenograft model ( Fig. 2A) (Fig. 2C) .
To assess the histological severity of lung metastasis, Ki-67 immunostaining were performed on lung sections to detect human metastatic cells (Fig. 2B and D) [18] . Metastatic nodules were scored according to the number of Ki-67 positive cells: severity-1 (Ͻ3 cells), severity-2 (between 3 and 20 cells) and severity-3 (Ͼ20 cells). As previously reported [18] , the severity of (Fig. 2B) . In sharp contrast, after intravenous cell inoculation, neither the number nor the severity of lung metastasis was affected by MT4-MMP expression (Fig. 2D) . (Fig. 3A) in comparison with those of control xenografts which were apposed to endothelial cells (Fig. 3B) (Fig. 3C) . In contrast, in control xenografts, intravasation process was never detected and their vessels displayed a thick intact basement membrane supporting apposed endothelial (Fig. 3D) . (Fig. 4B) 
Fig. 2 Effect of MT4-MMP on lung metastases. MDA-MB-231 breast cancer cells expressing (MT4 clones) or not (CTR clones) MT4-MMP were injected into immunodeficient mice either subcutaneously (spontaneous model of metastasis: A and B) or intravenously (experimental model of metastasis: C, D; E). (A)-(D) After 6 weeks of incubation, subcutaneously-(A, B) and intravenously-(C,
D
metastasis was drastically increased by MT4-MMP expression after subcutaneous injection
We have then evaluated the ability of cells to adhere and extravasate from blood vessels into the lungs of mice in a short-term assay. After intravenous injection of cells pre-labelled with a red-fluorescent cell tracker (n ϭ 10), lung vasculature was visualized 48 hrs latter by perfusion with a FITC-conjugated lectin. Remaining adhering/extravasating tumour were detected in the lung of 100% mice and no difference was observed between mice injected with MT4-MMP expressing cells (MT4 clones) or control cells (CTR clones) (Fig. 2E). All these data support the notion that MT4-MMP does not affect the extravasation efficiency of cancer cells to the lungs.
MT4-MMP overexpression affects intratumoral blood vessel size and perivascular cell distribution
We next investigated the primary tumour vascular architecture by transmission electron and fluorescent microscopic analysis. As opposed to similarities in the ultrastructural features of endothelial cells, explicit differences were noted between the two experimental groups with regard to endothelial cell and pericyte interactions. As previously described in other types of tumours [23, 25], basement membranes wrapping around tumour pericytes were abnormally thick, irregular and sometimes absent in both experimental conditions (data not shown). However, pericytes of xenografts expressing MT4-MMP were irregularly shaped, extended cytoplasmic processes and were loosely associated with endothelial cells
. Interestingly, intravasation of tumour cells were observed in MT4-MMP expressing xenografts, in which tumour cells extended protrusions into the lumen of vessels (in 3 out of 25 vessels observed)
Functional vascular tree of subcutaneous xenografts was then analysed by fluorescent microscopic observation of thick tumour sections. Tumour vessels washed free of blood were visualized by intraluminal staining with a FITC-conjugated lectin and perivascular cells were immunostained for ␣-SMA. Xenografts expressing MT4-MMP were characterized by enlarged blood vessels
Fig. 3 Transmission electron micrographs of blood vessels in breast cancer xenografts. Transfectants were subcutaneously injected into Rag-1 immunodeficient mice. After 4 weeks of incubation, ultrathin sections of xenografts expressing (Xenograft MT4; A, C) or not (Xenograft CTR; B, D) MT4-MMP were analysed with a Jeol 100 CX II transmission electron microscope at 60 kV. (A), (B) Pericytes (p) are present in both conditions but are irregularly shaped, extend more frequent cytoplasmic processes (black arrows) and are loosely associated with endothelial cells (ec) in tumours expressing MT4-MMP (A) compared to control tumours (B). (C), (D) Intravasating tumour cells (black arrow-head ) were preferentially observed in the lumen (l ) of blood vessels of xenografts expressing MT4-MMP (C) in contrast with control xenografts where tight associations between endothelial cells (ec) were observed (D). Rc, red blood cell. (A) and (B) at 8000-fold magnification (scale bar ϭ 2 m). (C) and (D) at 13,000-fold magnification (scale bar ϭ 1 m).
compared with control xenografts (Fig. 4A) (Fig. 4C) (Fig. 4D) Fig. 4A and B) , we set up a computer-assisted quantification using a grid of SMA ϩ cell distribution ( Fig. 4A and B; [26, 27] Fig. 5A and C) . However, 24 hrs after injection, the probe had extravasated and strongly accumulated in tumour areas of MT4-MMP expressing xenografts compared to the control xenografts (Fig. 5B and C) . [9, 28, 29] [18, [30] [31] [32] . Moreover their mechanisms of action and the specific steps of the metastatic cascade affected by these MMPs are unknown.
. The density of large vessels was twofold higher (P ϭ 0.01) in tumours expressing MT4-MMP as compared to control tumours (data not shown) whereas no significant difference in the total blood vessel density was observed between both conditions as assessed by quantification of the total number of vessels either present on the whole tumour section
or on 'hot spots' tumour areas (data not shown). However, an increase of the mean cross-sectioned blood vessel area (P ϭ 0.002) was noticed in MT4-MMP expressing xenografts (Fig. 4E). This vascular enlargement further confirms the effect of MT4-MMP expression on vessel architecture rather than on vascular density. In order to quantify the detachment of pericytes observed in the enlarged vessels of tumour expressing MT4-MMP (
right upper corners). More than 800 and 400 blood vessels from 10 MT4-MMP-expressing and 5 control xenografts, respectively, were analysed. Perivascular cell distribution calculated as a distance function from the tumour blood vessels, shows that the density of 'detached' mural cells present at 5, 10 or 15 m from endothelial cells were twofold higher in MT4-MMP expressing tumours compared to control xenografts (Fig. 4F). These data reflect impaired pericytes-endothelial cells interactions which is consistent with the transmission electron and fluorescent microscopic observations.
MT4-MMP effect on blood vessel morphology is associated with an increase of vessel leakage
In order to verify whether the strong effect of MT4-MMP on blood vessel architecture could increase the permeability of vessels, we have used AngioSense680 vascular probe which is a fluorescent polymeric macromolecule of 250 kD. Due to its high molecular size, this probe remains in the blood for a long time and can extravasate into tissues containing blood vessels that have large gaps between endothelial cells. This phenomenon, called 'enhanced permeability and retention' effect, is well known to target tumour containing leaky blood vessels
. This probe was therefore used to assess in vivo vascular leak of blood vessels in the xenografts expressing or not MT4-MMP. Seven hours after its intravenous injection, the AngioSense680 was uniformly distributed in the vasculature of all mice bearing tumours and no difference of fluorescence could be observed between xenografts either expressing or not MT4-MMP (
Discussion
The direct implication of MMPs in tumour progression is extensively documented and an increasing number of evidence show that MMP could have a much broader role in the metastatic process than initially expected, including their intervention in key steps of the metatastatic cascade such as angiogenesis, intravasation, extravasation and initiation/maintenance of secondary tumour growth
. However, to date, very few MMPs (MMP-7, MMP-8, MT1-MMP, MT4-MMP) have been described to directly modulate the dissemination of cancer cells at distance from a primary tumour, as assessed in spontaneous models of metastasis (subcutaneous xenografts)
In the present study, by using different approaches of immunohistological, ultrastructural and in vivo imaging analyses, we provide evidence that the pro-metastatic effect of MT4-MMP occurs by affecting the haematogenous route of tumour cell spreading rather than the lymphatic way. Indeed, we demonstrate that MT4-MMP does not affect the incidence of lymph node metastasis nor the [9, 33] while extravasation is qualified as a rather efficient process [28, 34] . [35, 36] and genetic engineered mice with blood vessel structural fragilities [37] develop more haematogenous metastasis. The presence of pericytes and their interaction with endothelial cells are thought to limit tumour metastatic dissemination as demonstrated by studies using mouse tumour models with loss/gain of NCAM or PDGF-B lacking the motif necessary to its endothelial retention [35, 36] . Therefore, [14] or in endothelial and perivascular cells of human endometrium in vitro [38] and in vivo during menstrual phases associated with high angiogenic activities [39] . Our paper sheds light on the contribution of MT4-MMP in metastatic dissemination in agreement with the relationship recently established between MT4-MMP expression and the transition from pre-invasive to invasive breast cancer [40] .
Fig. 4 Effect of MT4-MMP on tumour blood vessel morphology and perivascular cells distribution. Functional vascular tree of xenografts expressing or not MT4-MMP was visualized by intravenous injection of a (FITC)-labelled lectin in tumour-bearing mice (n ϭ 10). (A), (B) Fluorescent photomicrographs of representative sections of xenografts expressing (A) or not (B) MT4-MMP and showing an enlargement of FITC-lectin-labelled blood vessels (in green) as well as
Given 
